Cargando…

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials

Radiographic endpoints including response and progression are important for the evaluation of new glioblastoma therapies. The current RANO criteria was developed to overcome many of the challenges identified with previous guidelines for response assessment, however, significant challenges and limita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellingson, Benjamin M., Wen, Patrick Y., Cloughesy, Timothy F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398984/ https://www.ncbi.nlm.nih.gov/pubmed/28108885 http://dx.doi.org/10.1007/s13311-016-0507-6

Ejemplares similares

Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital “Flipbooks” to Control Systems Theory
por: Ellingson, Benjamin M., et al.
Publicado: (2022)

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
por: Chinot, Olivier L., et al.
Publicado: (2013)

Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients
por: Smedley, Nova F., et al.
Publicado: (2018)

The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I–III Studies
por: Cho, Nicholas S., et al.
Publicado: (2023)

Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
por: Ellingson, Benjamin M, et al.
Publicado: (2023)

Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab
por: Leu, Kevin, et al.
Publicado: (2014)

Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
por: Shidoh, Satoka, et al.
Publicado: (2022)

Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice
por: Chukwueke, Ugonma N, et al.
Publicado: (2019)

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma
por: Ellingson, Benjamin M, et al.
Publicado: (2021)

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
por: Wen, Patrick, et al.
Publicado: (2023)

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
por: Cloughesy, Timothy F, et al.
Publicado: (2020)

Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma
por: Chang, Warren, et al.
Publicado: (2015)

Evolution and implementation of radiographic response criteria in neuro-oncology
por: Ramakrishnan, Divya, et al.
Publicado: (2023)

mTOR signaling in glioblastoma: lessons learned from bench to bedside
por: Akhavan, David, et al.
Publicado: (2010)

Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma
por: Oshima, Sonoko, et al.
Publicado: (2023)

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
por: Iwanami, Akio, et al.
Publicado: (2013)

Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma
por: Patel, Kunal S., et al.
Publicado: (2020)

Evaluation of early imaging response criteria in glioblastoma multiforme
por: Gladwish, Adam, et al.
Publicado: (2011)

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study
por: Brenner, Andrew J, et al.
Publicado: (2020)

Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
por: Singh, Kirit, et al.
Publicado: (2022)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010)

Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma
por: Hathout, Leith, et al.
Publicado: (2016)

Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma
por: Takada, Juichi, et al.
Publicado: (2015)

Strict clinical and radiographic criteria for reduction of CSF shunt placement in patients with spinal myelomeningocele
por: Wiwanitkit, Viroj
Publicado: (2010)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
por: Banerjee, Pia, et al.
Publicado: (2015)

Experiences with the European guidelines on quality criteria for radiographic images in Tanzania
por: Muhogora, W. E., et al.
Publicado: (2001)

Cholestasis in patients with Cockayne syndrome and suggested modified criteria for clinical diagnosis
por: Abdel Ghaffar, Tawhida Y, et al.
Publicado: (2011)

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
por: Cloughesy, Timothy F, et al.
Publicado: (2018)

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
por: Wen, Patrick Y, et al.
Publicado: (2018)

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
por: Cloughesy, Timothy F., et al.
Publicado: (2019)

Inclusion and Exclusion Criteria of Clinical Trials for Insomnia
por: Huls, Hendrikje, et al.
Publicado: (2018)

Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials
por: Lieberman, Frank
Publicado: (2017)

Corticosteroid-Induced Regression of Glioblastoma: A Radiographic Conundrum
por: Cuoco, Joshua A., et al.
Publicado: (2019)

Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival
por: Wirsching, Hans-Georg, et al.
Publicado: (2023)

Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance
por: Wu, Si-Han, et al.
Publicado: (2014)

Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma
por: Taslimi, Shervin, et al.
Publicado: (2021)

Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients
por: Yong, William H., et al.
Publicado: (2015)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
por: Van Dyk, Kathleen, et al.
Publicado: (2022)

Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy
por: Pope, Whitney B., et al.
Publicado: (2011)

Use of Radiographic Criteria to Predict Outcomes Following Surgery for Pancreatic Cancer
por: Reynolds, Rae Brana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_47pfdmtcg61aaoujh0svhh7bep